Scientific Background and Reference Sources
ACMG. (2011). Technical Standards and Guidelines for CFTR Mutation Testing. STANDARDS AND GUIDELINES FOR CLINICAL GENETICS LABORATORIES. http://dx.doi.org/10.1038/gim.2014.93
ACOG. (2017). Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol, 129(3), e41-e55. https://doi.org/10.1097/aog.0000000000001952
Avram, C. M., Dyer, A. L., Shaffer, B. L., & Caughey, A. B. (2021). The cost-effectiveness of genotyping versus sequencing for prenatal cystic fibrosis carrier screening. Prenatal Diagnosis, 41(11), 1449-1459. https://doi.org/10.1002/pd.6027
Baker, M. W., Atkins, A. E., Cordovado, S. K., Hendrix, M., Earley, M. C., & Farrell, P. M. (2016). Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. Genet Med, 18(3), 231-238. https://doi.org/10.1038/gim.2014.209
Barrett, P. M., Alagely, A., & Topol, E. J. (2012). Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet, 21(R1), R66-71. https://doi.org/10.1093/hmg/dds345
Bell, S. C., De Boeck, K., & Amaral, M. D. (2015). New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther, 145, 19-34. https://doi.org/10.1016/j.pharmthera.2014.06.005
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., Hodkova, P., Kashirskaya, N., Kirszenbaum, M. N., Madge, S., Oxley, H., Plant, B., Schwarzenberg, S. J., Smyth, A. R., Taccetti, G., . . . Drevinek, P. (2018). ECFS best practice guidelines: the 2018 revision. J Cyst Fibros, 17(2), 153-178. https://doi.org/10.1016/j.jcf.2018.02.006
CF Foundation, U., Johns Hopkins University, The Hospital for Sick Children. (2023). The Clinical and Functional TRanslation of CFTR (CFTR2). https://www.cftr2.org/resources
Clancy, J. P., & Jain, M. (2012). Personalized medicine in cystic fibrosis: dawning of a new era. Am J Respir Crit Care Med, 186(7), 593-597. https://doi.org/10.1164/rccm.201204-0785PP
Clancy, J. P., Johnson, S. G., Yee, S. W., McDonagh, E. M., Caudle, K. E., Klein, T. E., Cannavo, M., & Giacomini, K. M. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther, 95(6), 592-597. https://doi.org/10.1038/clpt.2014.54
Cohen-Cymberknoh, M., Shoseyov, D., & Kerem, E. (2011). Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med, 183(11), 1463-1471. https://doi.org/10.1164/rccm.201009-1478CI
Coty, W. A. (2006, February 28). eSensor® Cystic Fibrosis Carrier Detection System 510(k) Summary. https://pathsurveyor.com/api/pmn_pdf?knumber=K060543
Deignan, J. L., Astbury, C., Cutting, G. R., del Gaudio, D., Gregg, A. R., Grody, W. W., Monaghan, K. G., Richards, S., & Committee, A. L. Q. A. (2020). CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics In Medicine, 22(8), 1288-1295. https://doi.org/10.1038/s41436-020-0822-5
Deignan, J. L., Gregg, A. R., Grody, W. W., Guo, M. H., Kearney, H., Monaghan, K. G., Raraigh, K. S., Taylor, J., Zepeda-Mendoza, C. J., & Ziats, C. (2023). Updated recommendations for CFTR carrier screening: A position statement of the American College of Medical Genetics and Genomics (ACMG). Genetics In Medicine, 25(8), 100867. https://doi.org/10.1016/j.gim.2023.100867
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., Legrys, V. A., Massie, J., Parad, R. B., Rock, M. J., & Campbell, P. W., 3rd. (2008). Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr, 153(2), S4-s14. https://doi.org/10.1016/j.jpeds.2008.05.005
Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., Howenstine, M., McColley, S. A., Rock, M., Rosenfeld, M., Sermet-Gaudelus, I., Southern, K. W., Marshall, B. C., & Sosnay, P. R. (2017). Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr, 181s, S4-S15.e11. https://doi.org/10.1016/j.jpeds.2016.09.064
FDA. (2006a). Decision Summary ESENSOR CYSTIC FIBROSIS CARRIER DETECTION TEST 510(k) Premarket Notification. http://www.accessdata.fda.gov/cdrh_docs/reviews/K051435.pdf
FDA. (2006b). Decision Summary Tag It Cystic Fibrosis Carrier Detection System 510(k) Premarket Notification.
Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K043011.pdf
FDA. (2007). Decision Summary Cystic Fibrosis Genotyping Assay 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K062028.pdf
FDA. (2008). Decision Summary Inplex CF Molecular Test 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K063787.pdf
FDA. (2009a). Decision Summary eSensor® CF Genotyping Test 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K090901.pdf
FDA. (2009b). Decision Summary Verigene® CFTR and Verigene® CFTR PolyT Nucleic Acid Tests 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K083294.pdf
FDA. (2009c). Decision Summary xTAG® Cystic Fibrosis 60 Kit v2 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K083845.pdf
FDA. (2013a). Decision Summary Illumina MiSeqDxTM Cystic Fibrosis Clinical Sequencing Assay 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K132750.pdf
FDA. (2013b). Decision Summary Illumina MiSeqDx™ Cystic Fibrosis 139-Variant Assay 510(k) Premarket Notification.
U.S. Food and Drug Administration Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K124006.pdf
FDA. (2016a). XTAG Cystic Fibrosis 39 Kit V2.
https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163347.pdf
FDA. (2016b). XTAG Cystic Fibrosis 60 Kit V2, XTAG Data Analysis Software (TDAS) CFTR.
https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163336.pdf
Gregg, A. R., Aarabi, M., Klugman, S., Leach, N. T., Bashford, M. T., Goldwaser, T., Chen, E., Sparks, T. N., Reddi, H. V., Rajkovic, A., Dungan, J. S., Practice, A. P., & Guidelines, C. (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics In Medicine, 23(10), 1793- 1806. https://doi.org/10.1038/s41436-021-01203-z
Grosse, S. D., Boyle, C. A., Botkin, J. R., Comeau, A. M., Kharrazi, M., Rosenfeld, M., & Wilfond, B. S. (2004). Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep, 53(Rr-13), 1-36. https://pubmed.ncbi.nlm.nih.gov/15483524/
Hendrix, M. M., Cuthbert, C. D., & Cordovado, S. K. (2020). Assessing the Performance of Dried-Blood-Spot DNA Extraction Methods in Next Generation Sequencing. International Journal of Neonatal Screening, 6(2), 36. https://doi.org/10.3390/ijns6020036
Hologic. (2008). InPlex Molecular Test. https://www.hologic.com/sites/default/files/packageinsert/Hologic%20CF%20IVD%20Package%20Insert.pdf#:~:text=SUMMARY%20AND%20EXPLANA TION%20A.%20Clinical%20Description%3A%20The%20InPlex%C2%AECF,establish%20the%20diagn osis%20of%20CF%20in%20an%20individual.
Illumina. (2013). Illumina MiSeqDx™ Cystic Fibrosis 139-Variant Assay. https://support.illumina.com/content/dam/illumina-marketing/documents/clinical/miseqdx-cystic-fibrosis139-variant-assay-data-sheet-1000000006359.pdf
Kessels, S. J. M., Carter, D., Ellery, B., Newton, S., & Merlin, T. L. (2020). Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics review. Genet Med, 22(2), 258-267. https://doi.org/10.1038/s41436-019-0641-8
Langfelder-Schwind, E., Karczeski, B., Strecker, M. N., Redman, J., Sugarman, E. A., Zaleski, C., Brown, T., Keiles, S., Powers, A., Ghate, S., & Darrah, R. (2014). Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns, 23(1), 5-15. https://doi.org/10.1007/s10897-013-9636-9
Lim, R. M., Silver, A. J., Silver, M. J., Borroto, C., Spurrier, B., Petrossian, T. C., Larson, J. L., & Silver, L. M. (2016). Targeted mutation screening panels expose systematic population bias in detection of cystic fibrosis risk. Genet Med, 18(2), 174-179. https://doi.org/10.1038/gim.2015.52
Luminex. (2024). xTAG® Cystic Fibrosis 71 v2 Kit https://www.luminexcorp.com/cystic-fibrosis/#overview
Lyon, E., Schrijver, I., Weck, K. E., Ferreira-Gonzalez, A., Richards, C. S., & Palomaki, G. E. (2014). Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys [Original Research Article]. Genetics In Medicine, 17, 219. https://doi.org/10.1038/gim.2014.93
Morris-Rosendahl, D. J., Edwards, M., McDonnell, M. J., John, S., Alton, E. W., Davies, J. C., & Simmonds, N. J. (2020). Whole Gene Sequencing of CFTR Reveals a High Prevalence of the Intronic Variant c.3874- 4522A>G in Cystic Fibrosis. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.201908-1541LE
NICE. (2017). Cystic fibrosis: diagnosis and management.
https://www.nice.org.uk/guidance/ng78/chapter/Recommendations#diagnosis-of-cystic-fibrosis
PCRM. (2023, February 16). Nutrition Guide for Clinicians: Cystic Fibrosis. Physicians Committee for Responsible Medicine. https://nutritionguide.pcrm.org/nutritionguide/view/Nutrition_Guide_for_Clinicians/1342064/all/Cystic_Fi brosis
Pletcher, B. A., & Bocian, M. (2006). Preconception and prenatal testing of biologic fathers for carrier status. American College of Medical Genetics. Genet Med, 8(2), 134-135. https://doi.org/10.1097/01.gim.0000200948.58427.e2
Pritchard, L. L. (2016). Respiratory Conditions Update: Cystic Fibrosis. FP Essent, 448, 35-43. https://www.ncbi.nlm.nih.gov/pubmed/27576234
Ren, C. L., Morgan, R. L., Oermann, C., Resnick, H. E., Brady, C., Campbell, A., DeNagel, R., Guill, M., Hoag, J., Lipton, A., Newton, T., Peters, S., Willey-Courand, D. B., & Naureckas, E. T. (2018). Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis. Ann Am Thorac Soc, 15(3), 271-280. https://doi.org/10.1513/AnnalsATS.201707-539OT
Schrijver, I., Pique, L., Graham, S., Pearl, M., Cherry, A., & Kharrazi, M. (2016). The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing. J Mol Diagn, 18(1), 39-50. https://doi.org/10.1016/j.jmoldx.2015.07.005
Sharma, D., Xing, S., Hung, Y. T., Caskey, R. N., Dowell, M. L., & Touchette, D. R. (2018). Costeffectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet J Rare Dis, 13(1), 172. https://doi.org/10.1186/s13023-018-0914-3
Sicko, R. J., Stevens, C. F., Hughes, E. E., Leisner, M., Ling, H., Saavedra-Matiz, C. A., Caggana, M., & Kay, D. M. (2021). Validation of a Custom Next-Generation Sequencing Assay for Cystic Fibrosis Newborn Screening. Int J Neonatal Screen, 7(4). https://doi.org/10.3390/ijns7040073
Smyth, A. R., Bell, S. C., Bojcin, S., Bryon, M., Duff, A., Flume, P., Kashirskaya, N., Munck, A., Ratjen, F., Schwarzenberg, S. J., Sermet-Gaudelus, I., Southern, K. W., Taccetti, G., Ullrich, G., & Wolfe, S. (2014). European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 13, S23-S42. https://doi.org/10.1016/j.jcf.2014.03.010
Sosnay, P. R., Siklosi, K. R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A. S., Amaral, M. D., Dorfman, R., Zielenski, J., Masica, D. L., Karchin, R., Millen, L., Thomas, P. J., Patrinos, G. P., Corey, M., Lewis, M. H., Rommens, J. M., Castellani, C., . . . Cutting, G. R. (2013). Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet, 45(10), 1160- 1167. https://doi.org/10.1038/ng.2745
Stafler, P., Mei-Zahav, M., Wilschanski, M., Mussaffi, H., Efrati, O., Lavie, M., Shoseyov, D., CohenCymberknoh, M., Gur, M., Bentur, L., Livnat, G., Aviram, M., Alkrinawi, S., Picard, E., Prais, D., Steuer, G., Inbar, O., Kerem, E., & Blau, H. (2016). The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening. J Cyst Fibros, 15(4), 460-466. https://doi.org/10.1016/j.jcf.2015.08.007
Straniero, L., Solda, G., Costantino, L., Seia, M., Melotti, P., Colombo, C., Asselta, R., & Duga, S. (2016). Whole-gene CFTR sequencing combined with digital RT-PCR improves genetic diagnosis of cystic fibrosis. J Hum Genet. https://doi.org/10.1038/jhg.2016.101
Sugunaraj, J. P., Brosius, H. M., Murray, M. F., Manickam, K., Stamm, J. A., Carey, D. J., & Mirshahi, U. L. (2019). Predictive value of genomic screening: cross-sectional study of cystic fibrosis in 50,788 electronic health records. NPJ Genom Med, 4, 21. https://doi.org/10.1038/s41525-019-0095-6
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., Konstan, M. W., McColley, S. A., McCoy, K., McKone, E. F., Munck, A., Ratjen, F., Rowe, S. M., Waltz, D., & Boyle, M. P. (2015). Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med, 373(3), 220-231. https://doi.org/10.1056/NEJMoa1409547
Wilschanski, M., Zielenski, J., Markiewicz, D., Tsui, L. C., Corey, M., Levison, H., & Durie, P. R. (1995). Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr, 127(5), 705-710. https://doi.org/10.1016/s0022-3476(95)70157-5
Specialty Matched Consultant Advisory Panel review 7/2019
Medical Director review 7/2019
Specialty Matched Consultant Advisory Panel review 7/2020
Medical Director review 7/2020
Specialty Matched Consultant Advisory Panel review 7/2021
Medical Director review 7/2021
Medical Director review 7/2022
Medical Director review 7/2023
Medical Director review 7/2024